Abstract-Neurotropin, an extract from the inflamed skin of vaccinia virus inoculated rabbits, has been observed clinically to be effective for treating pain in patients with lumbago, SMON and other neuropathies. In the present study, we examined the mechanism of the antinociceptive effect of neurotropin in mice in relation to administration routes, opioids, and noradrenergic or GABAergic drugs , by the tail pressure method. The antinociceptive effects of neurotropin were large when administered by the i.p. and intracisternal (i.cist.) routes, but comparatively small in the case of the intrathecal (i.th.) route. Neurotropin may thus act at the supraspinal level rather than on the spinal cord. The antinociceptive effect of neurotropin was not blocked by naloxone, and no cross-tolerance developed between neurotropin and morphine. The effect of neurotropin was blocked by phentolamine and reserpine, but not by atropine. Its effect was enhanced by GABA, muscimol, aminooxyacetic acid and diaminobutyric acid, but not by baclofen , and blocked by bicuculline methiodide. From these results, the antinociceptive action of neurotropin appears to be non-opioid in nature, and may possible be mediated by the noradrenergic and GABAergic systems, but unrelated to the cholinergic system. Neurotropin, an extract from the inflamed skin of vaccinia virus-inoculated rabbits, has been clinically reported to show analgesic effects in patients with severe pain (1-5) such as that occurring in cases of lumbago, cervicodynia, SMON and various neuropa thies. Thus, neurotropin can be effectively used to treat patients with chronic pain, but not those with acute pain. In animal experi ments, neurotropin has been reported to exert strong antinociceptive effects (6) on hyperalgesia (7, 8) in SART (specific alter nation of rhythm in temperature)-stressed (repeated cold-stressed) mice (9, 10), which show symptoms of vagotonic-type dysau tonomia (11), and in other types of hyper algesic mice (12).
Neurotropin, an extract from the inflamed skin of vaccinia virus-inoculated rabbits, has been clinically reported to show analgesic effects in patients with severe pain (1-5) such as that occurring in cases of lumbago, cervicodynia, SMON and various neuropa thies. Thus, neurotropin can be effectively used to treat patients with chronic pain, but not those with acute pain. In animal experi ments, neurotropin has been reported to exert strong antinociceptive effects (6) on hyperalgesia (7, 8) in SART (specific alter nation of rhythm in temperature)-stressed (repeated cold-stressed) mice (9, 10) , which show symptoms of vagotonic-type dysau tonomia (11) , and in other types of hyper algesic mice (12) .
However, the mechanism of its analgesic effect has so far not been clarified. In the present study, therefore, the antinociceptive effects of neurotropin on mice were in vestigated in relation to administration route , opioids, and noradrenergic or GABAergic agents.
Neurotropin was administered to mice centrally or peripherally.
Materials and Methods
Male ddY mice were used. They were housed at 22-24'C under a regime with a constant day-night rhythm and given food and water ad libitum. Normal healthy mice were used in most of the experiments, while in some experiments, SART-stressed mice were employed.
For SART stress loading, the mice were kept alternately at 24 °C and 4'C at 1-hr intervals from 9 a.m. to 4 p.m. and then at 4'C from 4 p.m. to 9 a.m. the following morning. This procedure was repeated for 5 consecutive days (9, 10) and then stopped on the morning of the 6th day of stress. The stressed animals were subjected to experi ments 1 hr or more after the cessation of stress.
Drugs were administered intracisternally, intrathecally or intraperitoneally.
Intracisternal (i.cist.) injection was carried out using a J-shaped needle (27 gauge) with a 40' curve 3.5 mm from the tip, ac cording to the method of Ueda et al. (13) , using mice weighing about 20 g. Each mouse was held manually for this purpose. The needle was inserted into the cleft between the occiput and atlas vertebra through the intact skin. The drug solution was injected at a volume of 10 /cl.
For administration of drugs directly into the spinal subarachnoid space, mice weighing about 25 g were given intrathecal (i.th.) injections (14) by lumbar puncture, directing a needle (30 gauge) into an intravertebral space approximately at the level of the 5th or 6th lumbar vertebra. The injection volume was 5/d.
The nociceptive threshold of the mice was determined by the modified tail pressure method using a Randall-Selitto Analgesy Meter (Ugo Basile). Mice were subjected to a force on the tail at a point 1 cm distant from the root. The force applied to the tail was increased at a constant rate of 16 g/sec. The force required to produce the escape reaction in a mouse was defined as the nociceptive threshold. The ratio of this force after treat ment to that before treatment was defined as the antinociceptive index. To assess the development of cross tolerance between morphine and neuro tropin, their antinociceptive effects were examined on the 4th day in mice rendered tolerant by 3 daily treatments with 10 mg/ kg/day of morphine, i.p., according to Kaneto and Kihara (15) .
The following drugs were used: Neuro tropin® (Nippon Zoki, 20 mg/ml), morphine hydrochloride (Takeda Neurotropin showed dose-dependent anti nociceptive effects when administered by any of the routes. The effects in SART stressed mice were significantly greater than those in non-stressed mice, especially by the i.p. and i.cist. routes. Also, significantly larger effects were produced by the i.cist. route than by the i.th. route at any of the corresponding doses, not only in non-stressed mice but also in SART-stressed mice. Neurotropin doses larger than 4 mg/kg were not examined using the i.th. route, because the administration volume was excessive for mice. 2. Antinociceptive effect of neurotropin, non opioid ?
The antinociceptive effect of neurotropin was compared with that of morphine, with or without naloxone pretreatment. The anti nociceptive effects of i.cist. morphine and neurotropin were observed 2 and 5 min after administrations and thereafter every 5 min to 30 min, and the data are shown in Fig. 2 .
The antinociceptive effect of morphine at a dose of 0.2 or 0.4 /cg/mouse was noted 2 min following i.cist. administration.
It reached a maximun and lasted for more than 30 min. This effect was inhibited by i.p.-preadminis tered naloxone at 0.5 or 2 mg/kg. The anti nociceptive effect of neurotropin, 50 or 100 /,,g/mouse, peaked 2 min after i.cist. adminis tration, gradually decreased and reached approximately the predrug level after 30 min. This effect in the case of neurotropin was not inhibited by naloxone pretreatment. Naloxone at 0.5 or 2 mg/kg, i.p., had no significant influence on the nociceptive threshold of mice.
A study was then made to determine whether cross-tolerance developed between neurotropin and morphine. The data are shown in Fig. 3 . In non-pretreated mice, the antinociceptive index induced by 10 mg/kg morphine, i.p., was 1.80, but in morphine-tolerant mice, it was 1.28. The antinociceptive index induced by 200 mg/kg neurotropin, i.p., was 1.26 The pre-drug nociceptive threshold was 101.8±0.5 g (mean±S.E.) in non-treated mice and 99.8±0.7 g in morphine-tolerant mice (not significantly different).
No. of animals: 4 mice/group. ***P<0.001, compared with the non-treated group (Student's t-test). Table 1 .
Phentolamine, a noradrenergic blocker, was administered simultaneously with neuro tropin by the same route, and it was found to inhibit the antinociceptive effect of neuro tropin by all modes of administration.
Reser pine, a depletor of catecholamines, which was i.p. administered 23 hr before neuro tropin, also inhibited the antinociceptive effect of neurotropin, but atropine, a cholin ergic blocker, which was i.p. administered 1 hr before neurotropin, failed to do so. Atropine doses larger than 10 mg/kg were not examined, because mice showed slightly stimulated behavior with a large dose (20 mg/kg) of atropine.
Next, the influence of GABAergic drugs on neurotropin was examined. GABA had no influence by the i.p. route, but by the i.cist. route, it enhanced the antinociceptive effect of neurotropin.
Bicuculline methiodide, a GABAA-antagonist, significantly inhibited the effect of neurotropin. Aminooxyacetic acid, a GABA-transaminase inhibitor, or diamino butyric acid, a GABA-reuptake inhibitor, sig nificantly strengthened the effect of i.cist. neurotropin.
In these cases, GABA and bicuculline methiodide were administered simultaneously with neurotropin by the same route, and aminooxyacetic acid and diamino butyric acid were i.p. administered 1 hr before neurotropin.
All these drugs except for neurotropin were administered at a dose that would not directly influence the nociceptive threshold in mice at the test time. 4. The antinociceptive effect of combined use of neurotropin and GABA agonists i.p. administration: GABA agonists were i.p. administered simultaneously with neuro tropin. These effects of neurotropin in combi nation with GABA agonists at fixed doses are shown in the left panel of Fig. 4 , and those of GABA agonists in combination with neuro tropin at fixed doses are shown on the right side. Two-way ANOVA showed no significant interaction among the treatments shown on panels and ( in Fig. 4 , and sig nificant interactions were observed among the treatments with neurotropin and baclofen shown in panels e (P<0.01) and ® (P< 0.001) in Fig. 4 . From the results of these analyses and the regression lines in Fig. 4 , the combined use of neurotropin and GABA showed the same antinociceptive effects as those due to neurotropin alone. The combined use of neurotropin and muscimol, a GABAA agonist, showed additive effects, as shown in panels © and ©. With the combined use of neurotropin and baclofen, a GABAB agonist, ANOVA revealed a highly significant inter action (P<0.01 in ( and P<0.001 in O), and the effects were additive at lower doses of baclofen, whereas at higher doses, no such effects were observed.
i.cist. administration: Neurotropin was i.cist. administered simultaneously with GABA agonists, and the data are shown in Fig. 5 in the same manner as for Fig. 4 . The com bined use of neurotropin and GABA showed additive antinociceptive effects, and the combination of neurotropin and muscimol also did so, as in the case of the i.p. route. ANOVA showed a highly significant (P< 0.001) interaction for the simultaneous ad ministration of neurotropin and baclofen, and the two drugs were antagonistic at higher doses of baclofen.
i.th. administration: Neurotropin was i.th. administered simultaneously with baclofen, and these data are shown in Fig. 6 . ANOVA showed significant differences between the treatments shown in the left panel (P<0.001) and the right panel (P<0.05) in Fig. 6 . For combined use of neurotropin and baclofen by the i.th. route, no additive effect was observed at higher doses of baclofen, as was also noted for administration by the i.p. and i.cist. routes. The pre-drug nociceptive threshold of these mice was 99.6±0.2 g (mean±S.E.).
Discussion
Neurotropin has been reported to show a larger antinociceptive effect on SART stressed mice than on non-stressed mice (6); and clinically, it has been effective on pain in patients with cervicodynia, post-herpetic neuralgia and other neuropathies. In this study, neurotropin administered by all of the i.p., i.cist. and i.th. routes, showed a larger effect on SARI-stressed mice, a model animal with chronic pain (16) , than on non stressed mice. Thus, the antinociceptive effect of neurotropin was large in diseased mice compared with its effect in normal healthy mice. This fact may be related to findings that SARI-stressed animals were in the state of reduced sympathetic tone (8, 11) , that some of the above-described pain on which neurotropin shows analgesic effects, are thought to have some relation to the sympathetic nervous system (17) (18) (19) , and that neurotropin had regulative actions on abnormal tone in autonomic nerves (20, 21) .
Effects of neurotropin produced by the i.cist. route were larger than those produced by the i.th. route, so that it appeared to act at the supraspinal level rather than in the spinal cord.
This study attempted to reveal part of the antinociceptive mechanism of neurotropin in normal mice, mainly in relation to opioids, noradrenergic and GABAergic drugs, although it will also be necessary to examine its re lation to other pain inhibitory systems, pain transmitters and other factors.
The antinociceptive effect of neurotropin is thought to be non-opioid in nature, because it was not blocked by the opiate antagonist naloxone, and no cross-tolerance developed between neurotropin and morphine.
The antinociceptive effect of neurotropin was blocked by phentolamine and reserpine, but not by atropine. It thus appears that the antinociceptive action of neurotropin may be mediated by a descending noradrenergic system, but unrelated to a cholinergic system.
The antinociceptive effect of neurotropin was enhanced by aminooxyacetic acid and diaminobutyric acid, which activate the GABAergic neuron by inhibiting GABA transaminase or GABA reuptake, and it was antagonized by bicuculline methiodide, a GABAA antagonist. Moreover, the combined use of neurotropin with GABA (i.cist.) or muscimol (i.p., i.cist.) exhibited additive effects, but combined use with baclofen did not do so. Thus, the action of neurotropin may be mediated by a GABAergic system, particularly the GABAA system.
With regard to its relation with anti nociception, GABA is known to be correlated with the action of morphine (22-27). The antinociceptive effect of morphine has been found to be enhanced by aminooxyacetic acid, but lessened by bicuculline (22). Also, GABA content is known to increase sig nificantly with the antinociceptive action of morphine (23, 24) in the dorsal part of the spinal cord, the ventrolateral part in the ventral thalamic nucleus and the lateral spinothalamic tract. It is thus likely that GABA plays a part in nociceptive inhibition in these areas. Although it should be deter mined whether neurotropin increases GABA content, GABA is certainly related to the antinociceptive action of neurotropin. Neurotropin has also been reported to inhibit the release of bradykinin-like sub stances induced by noxious stimuli applied to the rat hind paw (28), and it has been observed to inhibit both the first phase involving substance P and bradykinin and the second phase involving histamine and prostaglandin in hyperalgesic mice in the formalin test (12) .
In summary, neurotropin may exert analgesic effects both by acting on the central pain inhibitory system and directly and/or indirectly inhibiting the release of pain transmitters. 
